Invention Grant
US5670149A Lymphotoxin-.beta., Lymphotoxin-.beta. complexes, pharmaceutical
preparations and therapeutic uses thereof
失效
淋巴毒素-β，淋巴毒素-β复合物，药物制剂及其治疗用途
- Patent Title: Lymphotoxin-.beta., Lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof
- Patent Title (中): 淋巴毒素-β，淋巴毒素-β复合物，药物制剂及其治疗用途
-
Application No.: US476489Application Date: 1995-06-06
-
Publication No.: US5670149APublication Date: 1997-09-23
- Inventor: Jeffrey Browning , Carl F. Ware
- Applicant: Jeffrey Browning , Carl F. Ware
- Applicant Address: MA Cambridge CA Oakland
- Assignee: Biogen, Inc.,The University of California
- Current Assignee: Biogen, Inc.,The University of California
- Current Assignee Address: MA Cambridge CA Oakland
- Main IPC: A61K38/00
- IPC: A61K38/00 ; C07K14/525 ; A61K39/395
Abstract:
This invention relates to lymphotoxin-.beta., a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PNA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin-.beta. and other peptides such as lymphotoxin-.alpha. and to complexes comprising multiple subunits of lymphotoxin-.beta.. These proteins and complexes are useful in holding LT-.alpha. formed within the cell on the cell surface where the LT-.alpha./LT-.beta. complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-.alpha./LT-.beta. complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-.beta..
Public/Granted literature
- US5580934A Ring-opening hydrogenated copolymer and process for producing the same Public/Granted day:1996-12-03
Information query
IPC分类:
